Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.36
vs -0.15
Q3.23
N/A
-0.24
vs -0.14
Q4.23
N/A
-0.42
vs -0.09
Q1.24
N/A
-0.54
vs -0.18
Q2.24
N/A
-0.37
vs -0.36
Q3.24
N/A
-0.37
vs -0.24
Q4.24
N/A
-0.46
vs -0.42
Q1.25
N/A
-0.45
vs -0.54
Q2.25
N/A
-0.42
vs -0.37
Q3.25
N/A
-0.38
vs -0.37
Sales Growth
YoY
Current
Estimates
Q2.23
+22%
4.8M vs 3.9M
Q3.23
+16%
3.7M vs 3.2M
Q4.23
-15%
4.5M vs 5.4M
Q1.24
-34%
3M vs 4.5M
Q2.24
-24%
3.7M vs 4.8M
Q3.24
+21%
4.4M vs 3.7M
Q4.24
-36%
2.9M vs 4.5M
Q1.25
+5%
3.1M vs 3M
Q2.25
+8%
4M vs 3.7M
Q3.25
+141%
10.7M vs 4.4M
Return on Equity
QoQ
Q2.23
+6%
0.06
vs 0.04
Q3.23
-33%
-0.33
vs 0.06
Q4.23
-58%
-0.58
vs -0.33
Q1.24
-47%
-0.47
vs -0.58
Q2.24
-45%
-0.45
vs -0.47
Q3.24
-21%
-0.21
vs -0.45
Q4.24
-50%
-0.50
vs -0.21
Q1.25
-77%
-0.77
vs -0.50
Institutionnal Ownership
QoQ
Q2.23
110
110
vs 97
13%
Q3.23
114
114
vs 110
4%
Q4.23
135
135
vs 114
18%
Q1.24
157
157
vs 135
16%
Q2.24
154
154
vs 157
-2%
Q3.24
168
168
vs 154
9%
Q4.24
181
181
vs 168
8%
Q1.25
180
180
vs 181
-1%
globenewswire.com
8 hours ago
seekingalpha.com
10 hours ago
benzinga.com
11 hours ago
https://thefly.com
13 hours ago
globenewswire.com
16 hours ago
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
NASDAQ
Unprofitable
Unprofitable
-0.46Â ( -3.69%)
Relative Strenght
19
Volume Buzz
15%
Earning Acce
No
Dist 52w H.
38%Forecast
6692%2026-Revenue
77%2026-EPS
-498%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
24.50(104.17%)
Number of analyst
2
Last analyst upgrade/downgrade
Oppenheimer
downgradePrevious: Perform
2025-05-19
Now: Underperform
Raymond James
upgradePrevious: Outperform
2024-08-19
Now: Strong Buy
Raymond James
initialisePrevious: Not converted
2024-08-16
Now: Outperform
Oppenheimer
initialisePrevious: Not converted
2024-06-24
Now: Perform
Quote Panel
Key Metrics
Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How LQDA compares to sector?